<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273741</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 03 29</org_study_id>
    <nct_id>NCT00273741</nct_id>
  </id_info>
  <brief_title>Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients</brief_title>
  <acronym>Ritaline</acronym>
  <official_title>Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim/objective of this study is to evaluate the antiasthenic effect of methylphenidate
      with a visual analogical scale (VAS) after 7 days of treatment, in cancer patients, in
      palliative care, i.e. with a progressive or terminal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer patients in an advanced phase or who are terminally ill generally present with
      depression, pain, drowsiness, alterations of cognition, anorexia and other symptoms due to
      the progressive disease. The objective of the medical team of support and palliative care is
      to control these effects to maintain a quality of life. Particularly, the cancer patient in
      an advanced phase of the disease presents with important asthenia. In some patients, this
      asthenia is characterized by drowsiness or apathy. It always leads to ill-being and a
      sensation of bad adaptation. When an etiologic treatment is possible (correction of the
      anaemia, of the metabolic disorders, of the undernutrition, of the anorexia, of the insomnia,
      of the stubborn pain, of the psychological suffering), the asthenia can be fought. But, when
      it appears in patients not really in the end of life (life expectancy more than 1 month) and
      when no etiologic treatments are possible, other solutions must be considered, and all the
      more when the complaint is important with repeated requests for relief.

      Methylphenidate is an amphetamine first indicated for deficient attention disorders with
      hyperactivity in children more than 6 years old. Several studies have been realized to
      evaluate its effect in cancer patients in palliative care. Some studies showed, in
      particular, its effectiveness on asthenia because of a stimulant and an antidepressant
      action. The methylphenidate could have an anti-analgesic effect or co-analgesic effect. All
      these studies are observational and not randomized. So they have a small level of proof and
      they have not been realized in a population of asthenic patients in palliative care. So a
      randomized controlled clinical trial in this specific population needs to be experimented.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty of recrutement
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of 3 units between the two study groups of the subjective impression of asthenia measured at the first day before the beginning of the treatment with a visual analogical scale at day 7 (+/- 1 day)</measure>
    <time_frame>7 days AVS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>each day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogical scale of pain</measure>
    <time_frame>inclusion, day 1, 2, 3, 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>day 1, 7 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Fatigue Inventory-20 (MFI-20)</measure>
    <time_frame>day 1, 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>inclusion, 7 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Asthenia</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo comparator</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>2</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced phase of neoplasm without any treatment available.

          -  Life expectancy of more than 1 month

          -  Karnofsky index more than 50%

          -  Chemotherapy IV or immunotherapy SC stopped more than 3 weeks before the end of the
             study

          -  Asthenia more than 5/10 on the visual analogical scale

          -  Informed consent form signed

          -  Affiliation to social security

        Exclusion Criteria:

          -  Patients who can receive chemotherapy IV or immunotherapy SC in the month following
             the study

          -  Patients in whom disease can respond to chemotherapy

          -  Corticotherapy started less than 7 days before the study or potentially within the
             first week of the study

          -  Asthenia which can be easily corrected

          -  Contraindications to the amphetamines

          -  HADS score of anxiety and/or depression more than or egal to 17/21

          -  Potential surgery with general anesthesia in the first 7 days of the study

          -  Inability to quantify the sensation of asthenia on the visual analogical scale

          -  Pregnancy or feeding

          -  Guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillemette Laval, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital D'Annemasse</name>
      <address>
        <city>Annemasse</city>
        <zip>74107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Régional d'Accompagnement et de Soins Palliatifs,</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Equipe mobile de recherche et de soutien en soins pallitaifs</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Soins palliatif, Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Soins Palliatifs, Hôpital Lyon sud</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soins Palliatifs et Soins de support, Centre Léon Bérard, 28 rue Laënnec,</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité mobile de soutien et de soins palliatifs, Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMSP, Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMSP, hôpital Saint aAntoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praz-Coutant</name>
      <address>
        <city>Passy</city>
        <zip>74190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Soins Palliatifs</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMSP, Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992 Feb;48(2):163-6.</citation>
    <PMID>1589233</PMID>
  </reference>
  <reference>
    <citation>Wilwerding MB, Loprinzi CL, Mailliard JA, O'Fallon JR, Miser AW, van Haelst C, Barton DL, Foley JF, Athmann LM. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995 Mar;3(2):135-8.</citation>
    <PMID>7539701</PMID>
  </reference>
  <reference>
    <citation>Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol. 2002 Jan 1;20(1):335-9. Review.</citation>
    <PMID>11773187</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987 Jan;71(1):67-70.</citation>
    <PMID>3791269</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Driver L, Barnes EA, Willey J, Shen L, Palmer JL, Escalante C. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003 Dec 1;21(23):4439-43.</citation>
    <PMID>14645434</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mr Marie</name_title>
    <organization>Direction de la recherche clinique et de l'innovation</organization>
  </responsible_party>
  <keyword>palliative care</keyword>
  <keyword>methylphenidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

